One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008
Department of General Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba 260-0856, Japan.Journal of Hepato-Biliary-Pancreatic Sciences (Impact Factor: 2.99). 11/2009; 17(4):470-5. DOI: 10.1007/s00534-009-0207-2
Many authors at high-volume centers all over the world have reported improved outcomes of hilar cholangiocarcinoma by several aggressive surgical approaches such as extended hepatic resection, combined vascular resection, and hepatopancreaticoduodenectomy in recent years. There has been great progress in the surgical treatment of hilar cholangiocarcinoma with these previous efforts by aggressive hepatobiliary surgeons. In particular, surgical techniques, diagnostic modalities, and perioperative management have been remarkably improved as compared with before. Herein we report the surgical outcome for both hilar cholangiocarcinoma of Bismuth types II, III, and IV and intrahepatic cholangiocarcinoma involving the hepatic duct confluence during the recent 8-year period between 2001 and 2008 at our institution, the Department of General Surgery at Chiba University. From our recent experienced results, it can be concluded that the surgical strategy for hilar cholangiocarcinoma has been improved remarkably, and major surgical hepatectomy can be done with relative safety, and these aggressive surgical approaches, including combined vascular resection, may be warranted for the surgical treatment of hilar cholangiocarcinoma. However, the adoption of new innovative therapeutic approaches might be required for further improvement of surgical outcome of hilar cholangiocarcinoma.
Article: Resektion von Klatskin-Tumoren[Show abstract] [Hide abstract]
ABSTRACT: Klatskin-Tumoren können durch eine radikale Operationstaktik mit tumorferner Präparation kurativ behandelt und damit 5-Jahres-Überlebensraten von 30–50% erreicht werden. Dies erfordert zwingend eine Leberresektion en bloc mit extrahepatischer Gallengangresektion und oft auch eine zusätzliche vaskuläre Resektion. Trotzdem kann nicht immer der angestrebte Sicherheitsabstand von 0,5–1 cm jenseits der makroskopischen Tumorgrenzen eingehalten werden. Dabei gilt, dass anatomisch bedingt bei erweiterter Hemihepatektomie rechts mit Pfortadergabelresektion die Wahrscheinlichkeit eines ausreichenden Sicherheitsabstands höher ist als bei Hemihepatektomie links. Allerdings kommt bei einem Teil der Fälle aufgrund einer Atrophie des linken Lappens nur eine Hemihepatektomie links in Betracht. Sind beide Verfahren möglich, wird bei ausreichender Leberfunktion meist der erweiterten Hemihepatektomie rechts der Vorzug gegeben. Insbesondere Leberfunktionsstörungen, aber auch Galleleckagen nach anspruchsvoller biliärer Rekonstruktion – oft mit mehreren, zarten intrahepatischen Gallengängen – tragen zur Komplikationsrate bei diesem komplexen chirurgischen Krankheitsbild bei.
- [Show abstract] [Hide abstract]
ABSTRACT: This case involved a 75-year-old woman with obstructive jaundice who was diagnosed with hilar bile duct carcinoma. After endoscopic retrograde biliary drainage, the total bilirubin level was normalized. The indocyanine green test retention rate at 15min (ICGR15) was 26%. The liver uptake ratio (LHL15) by technetium-99m galactosyl human serum albumin (99mTc-GSA) liver scintigraphy was 0.87. Left hepatectomy was scheduled by CT volumetry. However, biliary drainage was insufficient, and the functional liver volume showed functional deterioration of the left liver. After percutaneous transhepatic biliary drainage, future remnant liver volume by 99mTc-GSA liver scintigraphy changed to 52% from 42%, and ICGR15 and LHL15 were improved to 16% and 0.914, respectively. Scheduled left hepatectomy was performed following the results of functional liver volume. The measurement of functional volume by 99mTc-GSA liver scintigraphy provides useful information with respect to segmental liver function for deciding operative indications. KeywordsBile duct carcinoma-Technetium-99m galactosyl human serum albumin liver scintigraphy-Functional liver volume-Biliary obstruction-Operative indication
- [Show abstract] [Hide abstract]
ABSTRACT: The aim of this review is to describe recent advances and topics in the surgical management of bile duct cancer. Radical resection with a microscopically negative margin (R0) is the only way to cure cholangiocarcinoma and is associated with marked survival advantages compared to margin-positive resections. Complete resection of the tumor is the surgeon's ultimate aim, and several advances in the surgical treatment for bile duct cancer have been made within the last two decades. Multidetector row computed tomography has emerged as an indispensable diagnostic modality for the precise preoperative evaluation of bile duct cancer, in terms of both longitudinal and vertical tumor invasion. Many meticulous operative procedures have been established, especially extended hepatectomy for hilar cholangiocarcinoma, to achieve a negative resection margin, which is the only prognostic factor under the control of the surgeon. A complete caudate lobectomy and resection of the inferior part of Couinaud's segment IV coupled with right or left hemihepatectomy has become the standard surgical procedure for hilar cholangiocarcinoma, and pylorus-preserving pancreaticoduodenectomy is the first choice for distal bile duct cancer. Limited resection for middle bile duct cancer is indicated for only strictly selected cases. Preoperative treatments including biliary drainage and portal vein embolization are also indicated for only selected patients, especially jaundiced patients anticipating major hepatectomy. Liver transplantation seems ideal for complete resection of bile duct cancer, but the high recurrence rate and decreased patient survival after liver transplant preclude it from being considered standard treatment. Adjuvant chemotherapy and radiotherapy have a potentially crucial role in prolonging survival and controlling local recurrence, but no definite regimen has been established to date. Further evidence is needed to fully define the role of liver transplantation and adjuvant chemo-radiotherapy.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.